1-13 of 13
Zhenya Hong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Ruidong Zhang, Yang Cao, Xiaofan Zhu, Zhenya Hong, Jianwen Xiao, Fei Li, Ju Gao, Hongling Peng, Yongmin Tang, Runming Jin, Sixi Liu, Yajuan Cui, Shaoyan Hu, Min Yu, Xiaojun Xu, Xiaoyan Wu, Xiaoxi Lu, Huirong Mai, Xiaoxi Zhou, Yingzi Zhang, Zhi Yang, Yufeng Huang, Xiao He, Liang Huang, Cheng Qian, Yicheng Zhang, Tianyou Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4205.
https://doi.org/10.1182/blood-2024-206408
Published: 2024
Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Qingqing Cai, Yi Xia, Liang Wang, Dongfeng Zeng, Hongyan Tong, Huiqiang Huang, Yuerong Shuang, Zhigang Peng, Ying Zhao, Xiaobo Wang, Xiuhua Sun, Yu Yang, Daoguang Chen, Zhenya Hong, Jinni Wang, Jun Cai, Wei Zhang, Rong Tao, Hong Cen, Jianzhen Shen, Yirong Jiang, Yan Gao, Xiaojie Fang, Man Nie, Xuanye Zhang, Bing Bai, Yuchen Zhang, Qihua Zou, Xi Li, Chunmei Yang, Xin Gao, Hao Xu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4450.
https://doi.org/10.1182/blood-2024-209224
Published: 2024
Journal Articles

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Zefeng Xu, Ling Pan, Zhenya Hong, Qingsong Yin, Xuelan Zuo, Qin Wen, Fan Yu, Chunkang Chang, Wei Ling, Dong Wang, Dawei Ding, Zhijian Xiao
Journal: Blood
Blood (2023) 142 (Supplement 1): 1829.
https://doi.org/10.1182/blood-2023-178956
Published: 2023
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 11688–11689.
https://doi.org/10.1182/blood-2022-157416
Published: 2022
Journal Articles

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Zhenya Hong, Zhi Yang, Xiaoxi Zhou, Gaoxiang Wang, Mi Zhou, Yingzi Zhang, Peiling Zhang, Jinjin Huang, Li Meng, Haitao Ruan, Min Xiao, Yunyan Li, Linling Wang, Meiling Wang, Wei Zhu, Qianzhen Zhang, Junjie Shen, Jianfeng Zhou, Cheng Qian, Liang Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 4625–4626.
https://doi.org/10.1182/blood-2022-162134
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 3598.
https://doi.org/10.1182/blood-2021-153937
Published: 2021
Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou, Zhenya Hong, Zheng Yao, Min Xiao, Liting Chen, Xia Mao, Li Zhu, Jin Wang, Lugui Qiu, Chunrui Li, Jianfeng Zhou
Journal: Blood
Blood (2021) 137 (21): 2890–2901.
https://doi.org/10.1182/blood.2020008936
Published: 2021
Includes: Supplemental data
Journal Articles

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Junning Cao, Zhiming Li, MD PhD, Jianfeng Zhou, MD PhD, Dongmei Ji, MD PhD, Weina Shen, PhD, Peng Sun, MD, Yu Wang, MD, Dengju Li, MD, Zhenya Hong, MDPhD, Gaoxiang Wang, MDPhD, Xianlin Duan, MD, Chen Yu, MD, Yu Cai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-136013
Published: 2020
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 929.
https://doi.org/10.1182/blood-2019-128468
Published: 2019
Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1408.
https://doi.org/10.1182/blood-2018-99-113714
Published: 2018
Journal Articles

A Novel Target of Histone Deacetylase Inhibitor, Involves in Mitochondria Membrane Protein Ubiquitination and Regulates Apoptosis.

Peng Wu, PHD, Yang Cao, PHD, Yuan Tian, PHD, Zhenya Hong, PHD, Lishi Sun, PHD, Lingli Gui, PHD, Yicheng Zhang, PHD, Ding Ma, PHD, Jianfeng Zhou, PhD
Journal: Blood
Blood (2007) 110 (11): 4187.
https://doi.org/10.1182/blood.V110.11.4187.4187
Published: 2007